News | December 10, 2023
Pfizer presents marstacimab Phase 3 Data at ASH 2023
Demonstrate significant bleed reduction in hemophilia A and B
Demonstrate significant bleed reduction in hemophilia A and B
Late-stage Fabhalta development program ongoing in multiple complement-mediated conditions
C-CAR031 is based on a novel GPC3-targeting CAR-T (AZD5851) designed by AstraZeneca using their transforming growth factor-beta receptor II
The agreement includes an upfront payment of US$15 million, regulatory and commercial milestones, and royalties
Carmot Therapeutics’s R&D portfolio of clinical stage incretins has great potential to treat obesity, diabetes and potentially other diseases
The workshop is specially curated for Ayurvedic medical officers from Delhi and Haryana
A new GSK survey shows a large number of adults do not understand how shingles may be triggered
Acquisition underscores Merck’s ongoing commitment to developing treatments for neurodegenerative diseases
Jan Ausahdhi exhibited demonstration stall during 42nd India International Trade Fair to spread awareness
Emphasizes the need for a collective effort on bolstering resilience across economies, societies, healthcare systems, education systems and infrastructure
Subscribe To Our Newsletter & Stay Updated
